Literature DB >> 2240375

Recurrence rate after discontinuation of long-term mebendazole therapy in alveolar echinococcosis (preliminary results).

R W Ammann1, R Hirsbrunner, J Cotting, U Steiger, P Jacquier, J Eckert.   

Abstract

The recurrence rate was investigated in 19 patients with non-resectable alveolar echinococcosis after discontinuation of a long-term therapy with mebendazole (average treatment 4.3 years). A control group consisted of 14 patients who underwent radical surgery and finished a course of prophylactic postoperative mebendazole treatment of 2 years. In the controls, no recurrence was observed after a post-therapy period averaging 3.5 years. In contrast, recurrence occurred in 7/19 patients (37%) with non-resectable alveolar echinococcosis an average of 1.6 years after discontinuation of the long-term mebendazole therapy. The absence of clinically detectable recurrence in the remaining 12 patients seems to be due either to spontaneous inactivation of alveolar echinococcosis preceding chemotherapy or too short post-therapy surveillance. The patients with recurrence responded favorably to reintroduction of chemotherapy. The data indicate that mebendazole therapy is parasitostatic rather than parasiticidal.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2240375     DOI: 10.4269/ajtmh.1990.43.506

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  27 in total

1.  Efficacies of albendazole sulfoxide and albendazole sulfone against In vitro-cultivated Echinococcus multilocularis metacestodes.

Authors:  K Ingold; P Bigler; W Thormann; T Cavaliero; B Gottstein; A Hemphill
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  In vitro activities of itraconazole, methiazole, and nitazoxanide versus Echinococcus multilocularis larvae.

Authors:  Stefan Reuter; Burkhard Manfras; Marion Merkle; Georg Härter; Peter Kern
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  [Alveolar echinococcosis: therapy with surgery, chemotherapy or a combination of the two?].

Authors:  R Ammann
Journal:  Langenbecks Arch Chir       Date:  1992

4.  Potential anti-echinococcal activity of alkylaminoethers.

Authors:  T Duriez; P Depreux; P Thuillier; D Afchain; A Marcincal; S Deblock
Journal:  Parasitol Res       Date:  1992       Impact factor: 2.289

5.  In vitro activities of benzimidazoles against Echinococcus multilocularis metacestodes.

Authors:  H Jura; A Bader; M Frosch
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

6.  Effects of Isoprinosine on Echinococcus multilocularis and E. granulosus metacestodes.

Authors:  M E Sarciron; S Walbaum; A F Petavy
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

Review 7.  Echinococcus granulosus infection: the challenge of surgical treatment.

Authors:  K Buttenschoen; D Carli Buttenschoen
Journal:  Langenbecks Arch Surg       Date:  2003-07-04       Impact factor: 3.445

8.  Alveolar echinococcosis: characterization of diagnostic antigen Em18 and serological evaluation of recombinant Em18.

Authors:  Yasuhito Sako; Minoru Nakao; Kazuhiro Nakaya; Hiroshi Yamasaki; Bruno Gottstein; Marshall W Lightowers; Peter M Schantz; Akira Ito
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

9.  Immunomodulative effect of glucan and/or glucan supplemented with zinc in albendazole therapy for murine alveolar echinococcosis.

Authors:  Jarmila Porubcová; Emília Dvoroznáková; Zuzana Sevcíková
Journal:  Parasitol Res       Date:  2007-05-12       Impact factor: 2.289

10.  Alveolar hydatid disease. Review of the surgical experience in 42 cases of active disease among Alaskan Eskimos.

Authors:  J F Wilson; R L Rausch; F R Wilson
Journal:  Ann Surg       Date:  1995-03       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.